PPARγ Agonists as a New Class of Effective Treatment for Ulcerative Colitis

被引：9

作者：

Desreumaux, Pierre ^{[1
]}

Dubuquoy, Laurent ^{[1
]}

机构：

[1] Univ Lille 2, Huriez Hosp, Digest Tract Dis & Nutr Dept, Lille, France

来源：

INFLAMMATORY BOWEL DISEASES | 2009年 / 15卷 / 06期

关键词：

ACTIVATED-RECEPTOR-GAMMA; CONTROLLED-TRIAL; CLINICAL-TRIAL; ROSIGLITAZONE; EXPRESSION; DISEASES; EVENTS;

D O I：

10.1002/ibd.20765

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：959 / 960

页数：2

共 17 条

[1] Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease [J].

Adachi, M. ;

Kurotani, R. ;

Morimura, K. ;

Shah, Y. ;

Sanford, M. ;

Madison, B. B. ;

Gumucio, D. L. ;

Marin, H. E. ;

Peters, J. M. ;

Young, H. A. ;

Gonzalez, F. J. .

GUT, 2006, 55 (08) :1104-1113

[2] Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone [J].

Dahabreh, Issa J. ;

Economopoulos, K. .

CLINICAL TRIALS, 2008, 5 (02) :116-120

[3] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[4] PPARγ as a new therapeutic in inflammatory bowel diseases [J].

Dubuquoy, L. ;

Rousseaux, C. ;

Thuru, X. ;

Peyrin, L. -Biroulet ;

Romano, O. ;

Chavatte, P. ;

Chamaillard, M. ;

Desreumaux, P. .

GUT, 2006, 55 (09) :1341-1349

[5] Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis [J].

Dubuquoy, L ;

Jansson, EÅ ;

Deeb, S ;

Rakotobe, S ;

Karoui, M ;

Colombel, JF ;

Auwerx, J ;

Pettersson, S ;

Desreumaux, P .

GASTROENTEROLOGY, 2003, 124 (05) :1265-1276

[6] Role of peroxisome proliferator-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological diseases [J].

Dubuquoy, L ;

Dharancy, S ;

Nutten, S ;

Pettersson, S ;

Auwerx, J ;

Desreumaux, P .

LANCET, 2002, 360 (9343) :1410-1418

[7] Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis [J].

Home, Philip D. ;

Pocock, Stuart J. ;

Beck-Nielsen, Henning ;

Gomis, Ramon ;

Hanefeld, Markolf ;

Jones, Nigel P. ;

Komajda, Michel ;

McMurray, John J. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :28-38

[8] Cardiovascular safety of rosiglitazone [J].

Krall, Ronald L. .

LANCET, 2007, 369 (9578) :1995-1996

[9] Rosiglitazone for active ulcerative colitis: A randomized placebo-controlled trial [J].

Lewis, James D. ;

Lichtenstein, Gary R. ;

Deren, Julius J. ;

Sands, Bruce E. ;

Hanauer, Stephen B. ;

Katz, Jeffrey A. ;

Lashner, Bret ;

Present, Daniel H. ;

Chuai, Shaokun ;

Ellenbergr, Jonas H. ;

Nessel, Lisa ;

Wu, Gary D. .

GASTROENTEROLOGY, 2008, 134 (03) :688-695

[10]

Lewis JD, 2001, AM J GASTROENTEROL, V96, P3323

← 1 2 →